Both medications represent a novel class of antibody treatments designed to block the COVID-19 pathogen . Originally , sotrovimab, developed by GSK , demonstrated considerable benefit against versions of https://gregorygrqs669571.aboutyoublog.com/53768131/sotrovimab-vir-7831-a-deep-investigation-into-the-antibody-treatment